Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk

Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk
复制标题

DOI:
10.1016/j.cdp.2006.09.007
复制
发表时间:
2006-01-01
影响因子:
--
通讯作者:
Alexandre, Claudio O. P.
Alexandre, Claudio O. P.
中科院分区:
其他
文献类型:
--
作者:
Damin, Andrea P. S.;Frazzon, Ana P. G.;Alexandre, Claudio O. P.

文献摘要

被引文献

相似文献

背景:TP 53基因密码子72处常见的Arg/Pro多态性已被研究为不同人群中癌症的危险因素。到目前为止,结果一直存在争议。我们的目的是调查这种多态性与巴西南部乳腺癌的关系,巴西南部是乳腺癌的高危地区。方法:收集118名原发性乳腺癌妇女和202名女性献血员的血液样本,通过聚合酶链反应-限制性片段长度多态性和DNA测序进行分析。各等位基因的相对频率在癌症组分别为Arg 0.75和Pro 0.25,在正常对照组分别为Arg 0.62和Pro 0.38(P < 0.001)。Arg/Arg基因型与乳腺癌风险增加显著相关(OR 2.9; 95% CI 1.43-3.6; P < 0.002)。之间没有相关性的基因型分布和特定的预后预测疾病outcome.Discussion:TP 53密码子72多态性可能与乳腺癌的发生,与Arg/Arg基因型与这种恶性肿瘤的易感性增加。(c)2006年国际预防肿瘤学会。由Elsevier Ltd.出版。保留所有权利。
Background: A common Arg/Pro polymorphism at codon 72 of the TP53 gene has been investigated as a risk factor for cancer in different populations. So far, the results have been controversial. Our purpose was to investigate the association of this polymorphism with breast carcinoma in women from Southern Brazil, a high-risk area for breast cancer.Methods: Blood samples collected from 118 women with primary breast carcinoma and from 202 female blood donors were analyzed through polymerase chain reaction-restriction fragment length polymorphism and DNA sequencing.Results: The relative frequency of each allele was 0.75 for Arg and 0.25 for Pro in patients with cancer, and 0.62 for Arg and 0.38 for Pro in normal controls (P < 0.001). The Arg/Arg genotype was significantly associated with an increased risk for breast cancer (OR 2.9; 95% Cl 1.43-3.6; P < 0.002). No correlation between the genotype distribution and specific prognostic predictors for the disease outcome was observed.Discussion: TP53 codon 72 polymorphism might be implicated in breast carcinogenesis, with the Arg/Arg genotype being associated with an increased susceptibility for this malignancy. (c) 2006 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.